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Background: To evaluate the efficacy of first-line bevacizumab-based chemotherapy for untreated metastatic
colorectal cancer (mCRC) based on age.
Methods: Eligibility criteria focused on M1 disease without prior palliative chemotherapy. Choice of chemotherapy
regimen was at the physician’s discretion. Predefined efficacy endpoints were response rate, progression-free and
overall survival (PFS, OS). Patients were analysed by age (<70 vs. ≥70 years, <75 vs. ≥75 years).
Results: Of 1777 patients, 27% and 12% were ≥70 and ≥75 years, respectively. PFS was shorter in elderly patients
(<70 vs. ≥70 years: 10.5 vs. 9.5 months, p = 0.074; <75 vs. ≥75 years: 10.5 vs. 8.9 months, p = 0.00019), as was OS
(<70 vs. ≥70 years: 25.8 vs. 22.7 months, p < 0.0008; <75 vs. ≥75 years: 25.8 vs. 20.8 months; p < 0.0001). In the
groups <70 and <75 years, PFS was longer in those receiving oxaliplatin-/irinotecan-containing regimens vs. those
receiving 5-FU/capecitabine (<70 years: 10.6 vs. 9.0 months; p = 0.0065; <75 years: 10.6 vs. 9.2 months; p = 0.028); no
difference in PFS was observed between oxaliplatin-/irinotecan-containing regimens vs. 5-FU/capecitabine
regimens in both elderly age-group comparisons (≥70 years: 9.7 vs. 9.2 months; ≥75 years: 8.3 and 9.0 months).
Conclusion: First-line bevacizumab-based chemotherapies were effective in German mCRC patients ≥75 years of
age, but PFS and OS were significantly shorter in this age group vs. younger patients.
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The incidence and prevalence of cancer are rising among
older populations in developed countries [1] with more
than 60% of all cancers being diagnosed in people >65 years
of age [2,3]. Focusing specifically on colorectal cancer,
almost 75% of patients with the disease are >65 years of age
and the median age at diagnosis is 70 years [4]. Despite this,
older patients are typically under-represented in clinical
trials, with <10% of patients enrolled in colorectal cancer
clinical trials being >70 years of age [5].* Correspondence: Ralf-Dieter.Hofheinz@medma.uni-heidelberg.de
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unless otherwise stated.In randomised trials involving patients with meta-
static colorectal cancer (mCRC), the addition of the
humanised monoclonal antibody bevacizumab to first-
and second-line therapies has resulted in significantly
improved progression-free survival (PFS) compared
with chemotherapy alone [6-8]. Recently, the AVEX
trial reported a clinically significant benefit of adding
bevacizumab to low doses of capecitabine (2000 mg/m2/
day) in patients aged ≥70 years not deemed suitable for
treatment with chemotherapy doublets. In this study,
patients with a median age of 76–77 years derived a
significant 4-month benefit in PFS (hazard ratio: 0.53,
95% CI: 0.41–0.69; p < 0.001) and a clinically, but not statis-
tically, significant overall survival (OS) benefit of 3.9 monthsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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bevacizumab + capecitabine over capecitabine alone [9].
In the randomised, open-label FOCUS2 trial, factorial
comparison of 459 elderly and frail patients with advanced
colorectal cancer found the addition of oxaliplatin versus
no addition provided some improvement in PFS, but the
finding was not significant (median 5.8 months [interquar-
tile range: 3.3–7.5] vs 4.5 months [2.8–6.4]; hazard ratio
0.84, 95% CI: 0.69–1.01, p = 0 · 07), while replacement of
fluorouracil with capecitabine did not improve global
quality of life scores [10]. A pooled analysis of elderly
mCRC patients from randomised clinical studies showed
that the addition of bevacizumab to chemotherapy
provided similar PFS and OS benefits in medically fit older
patients as in younger patients [11]. Similarly, in the
BRiTE prospective observational cohort study, which
included 363 patients ≥65 years of age, elderly patients
receiving bevacizumab had similar PFS as younger pa-
tients, although as expected OS diminished with increased
age [12]. However, despite these findings there is still a
relative paucity of data on the use of bevacizumab in daily
clinical practice in patients >70 years and particularly for
those who are >75 years of age.
Following the approval of bevacizumab in Germany
in 2005 for the treatment of unresectable advanced or
refractory CRC, an observational cohort study was
initiated to assess the efficacy and safety of bevacizu-
mab as part of first-line chemotherapy for mCRC in
German patients. Analyses were also performed to
investigate the efficacy and safety of treatment with
bevacizumab plus chemotherapy in elderly patients
(either ≥70 or ≥75 years) with mCRC compared with
younger patients (<70 or <75 years, respectively).Methods
Observational cohort design and patients
This was an observational cohort study of patients with
mCRC who had received no prior chemotherapy for
metastatic disease. To facilitate enrolment of a typical
mCRC population, eligibility criteria were minimised.
All patients scheduled to undergo first-line treatment
with bevacizumab were included. The choice of chemo-
therapy regimen was at the physicians’ discretion, but
was influenced by current registration status (i.e. 5-FU or
capecitabine alone or in combination with oxaliplatin or
irinotecan). The target was to recruit 1600 patients.
Detailed information on baseline data, antineoplastic
treatment, tumour development and safety were collected
up to termination of bevacizumab therapy, or for a period
of 12 months, in most cases. Thereafter, long-term assess-
ment data on key parameters were retrieved repeatedly by
additional fax forms for up to 6 years after initiation of
treatment.This was an observational study in which physicians’
choices were guided by drug registration status and
treatment guidelines (rather than the trial protocol). As
the study was started prior to 2007, it was in agreement
with the German FSA Codex [13] and the AMG
Amendment 12, there was no need/requirement for eth-
ics committee approval or written informed consent. For
non-interventional studies started in 2007 or later, the
FSA Codex asks for submission to the ethics committee
and to the regulators. Furthermore, in the European
Union, clinical research has to be performed according
to the Directive 2001/20/EC of the European Parliament
and of the Council on the approximation of the laws,
regulations and administrative provisions of the Member
States relating to the implementation of good clinical
practice in the conduct of clinical trials on medicinal
products for human use dating from April 2001. This
regulation differentiates between the requirements for
“interventional” and “non-interventional” studies. This
observational study clearly fulfills the criteria for “non-
interventional” as defined in Article 2, c.
Treatment
Patients received bevacizumab 5–10 mg/kg every 2 weeks
or 7.5–15 mg/kg every 3 weeks in combination with
chemotherapy; patients were also allowed to receive
bevacizumab monotherapy.
Endpoints
Predefined efficacy endpoints were investigator-assessed
response rate (as best response, unconfirmed), PFS (time
from start of first-line therapy to investigator-assessed
progression or death, whichever occurred first), and OS
(time from start of first bevacizumab administration to
death). Adverse events potentially related to antibody
treatment were recorded (by use of open questions) and
assessed, especially those of interest for bevacizumab, such
as hypertension, proteinuria, gastrointestinal perforation,
haemorrhage, and arterial/venous thromboembolic events.
An adverse drug reaction was defined as an event for
which a causal relationship with bevacizumab could not
be ruled out or was unknown. A serious adverse drug
reaction was defined as any event that resulted in death,
was incapacitating, or required inpatient hospitalisation/
prolongation of existing hospitalisation for treatment.
Data analysis
Database lock occurred in November 2011. Explora-
tory post-hoc subgroup analyses were performed to
evaluate the efficacy of treatment in patients ≥70 and
those <70 years of age, and those ≥75 and <75 years of
age. Analyses were based on the population of patients
who had received at least one dose of bevacizumab.
PFS and OS were recorded based on investigators’
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tors’ discretion) and analysed using Kaplan–Meier
methodology, with median survival times and 95%
confidence intervals (CIs). The curves were compared
using two-sided log-rank tests. The rate of adverse
events (all types and those of special interest for beva-
cizumab) were presented descriptively and summarised
by study treatment.Table 1 Patients’ baseline characteristics according to age





Median age, years (range) 61 (19–69)
















Local recurrence, n (%) 585 (51)
Median CEA, ng/mL (range) 20.9 (0–14 671)
Surgical removal of primary tumour, n (%) 1210 (93)












CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatieResults
Patients
Between January 2005 and June 2009, 1777 eligible
patients were enrolled at 261 sites in Germany; of these,
480 (27%) and 206 patients (12%) were ≥70 and ≥75 years
of age, respectively. Baseline characteristics according to
patient age are shown in Table 1. Elderly patients in either






297 (62) 985 (63) 123 (60)
183 (38) 586 (37) 83 (40)
73 (70–100) 63 (19–74) 77 (75–100)
153 (32) 598 (38) 58 (28)
251 (52) 785 (50) 113 (55)
56 (12) 147 (9) 28 (14)
11 (2) 11 (1) 4 (2)
1 (<1) 1 (<1) 0
8 (2) 29 (2) 3 (1)
332 (69) 1130 (72) 137 (67)
133 (28) 434 (28) 56 (27)
10 (2) 53 (3) 4 (2)
107 (22) 408 (26) 49 (24)
321 (67) 1007 (64) 138 (67)
124 (26) 476 (30) 53 (26)
35 (7) 88 (6) 15 (7)
220 (51) 711 (51) 94 (50)
20.7 (0.1–25305) 20.4 (0–25 305) 25.6 (0.1–6848)










nts could have >1 metastatic site.
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lapse; initial pT, pN and M stage; site of metastasis;
grading; carcinoembryonic antigen (CEA) level; white
blood cell count; and blood pressure. Fewer patients
aged ≥75 years vs. <75 years had received prior radio-
therapy (12% vs. 18%), although this difference was slightly
less in patients aged ≥70 years vs. <70 years (14% vs. 18%).
There were no differences between groups with respect to
previous (neo)adjuvant chemotherapy. Fewer elderly pa-
tients in both age groups had >1 organ involved and eld-
erly patients, again in both age groups, tended to have
poorer Eastern Co-operative Oncology Group (ECOG)
performance status (Table 1).
Treatment
The median duration of treatment was 7 months in all four
groups; patients <70, ≥70 and <75 years of age received a
median of 8 treatment cycles while those aged ≥75 years
received a median of 7.5 cycles. The differences between
the younger and older age groups in the treatment chemo-
therapy backbone received, irrespective of whether the ana-
lysis was performed at <70 vs. ≥70 or <75 vs. ≥75 years,
were: fewer older patients received doublet combinations at
the start of treatment while more older patients received
5-FU or capecitabine monotherapy (Figure 1). Patients’
baseline characteristics by chemotherapy regimen and age
are shown in Table 2.
Efficacy
In the overall/intent-to-treat (ITT) patient population, the
best objective response rate following bevacizumab-based
treatment was 60% (95% CI 58–63%; complete responseFigure 1 Bevacizumab-based therapy administered in cycle 1 accordi10%, partial response 51%). The investigator-assessed over-
all objective response rate (including all treatment regi-
mens) in patients aged <70 years was significantly greater
than that in those aged ≥70 years (62% vs. 55%; p = 0.0046
Fisher’s exact test; Table 3); similar findings were observed
in patients aged <75 years vs. those aged ≥75 years (61% vs.
51%; p = 0.0041 Fisher’s exact test; Table 3).
Median PFS in the ITT population was 10.2 months,
based on 1390 observed events. Median PFS in pa-
tients aged <70 years was longer than that in those
aged ≥70 years (10.5 vs. 9.5 months; hazard ratio [HR]:
1.11, 95% CI: 0.99–1.25; 2-sided log-rank test p = 0.074;
Figure 2A) and this reached statistical significance in
patients <75 vs. ≥75 years of age (10.5 vs. 8.9 months; HR:
1.36, 95% CI: 1.16–1.60; 2-sided log-rank test p = 0.00019;
Figure 2B). Corresponding values for median OS for
patients aged <70 vs. ≥70 years and <75 vs. ≥75 years were
25.8 vs. 22.7 months (HR: 1.28, 95% CI: 1.11–1.47; 2-sided
log-rank test p <0.0008; Figure 2C) and 25.8 vs. 20.8 months,
respectively (HR: 1.48, 95% CI: 1.23–1.80; 2-sided log-rank
test p <0.0001; Figure 2D).
Evaluation of PFS by chemotherapy regimen in pa-
tients <70 and <75 years of age showed PFS to be
higher in those patients receiving an oxaliplatin- or
irinotecan-based combination regimen compared with
the respective groups receiving 5-FU/capecitabine (<70 years:
10.6 and 9.0 months, log-rank test p = 0.0065; <75 years:
10.6 and 9.2 months, log-rank test p = 0.028); however, no
difference in PFS was observed between oxaliplatin- or
irinotecan-based combinations and 5-FU/capecitabine regi-
mens in both elderly age group comparisons (≥70 years: 9.7
and 9.2 months, log-rank test p = 0.52; ≥75 years: 8.3 andng to patient age.
Table 2 Patients’ baseline characteristics according to chemotherapy regimen and age


















Male 60 (57) 739 (63) 60 (58) 234 (64) 84 (58) 888 (64) 36 (57) 85 (62)
Female 45 (43) 426 (37) 44 (42) 133 (36) 62 (42) 508 (36) 27 (43) 51 (38)
Median age, years
(range)




(n = 103) (n = 1144) (n = 101) (n = 362) (n = 142) (n = 1372) (n = 62) (n = 134)
0 52 (50) 435 (38) 38 (38) 112 (31) 67 (47) 514 (37) 23 (37) 33 (25)
1 38 (37) 599 (52) 48 (48) 199 (55) 56 (39) 719 (52) 30 (48) 79 (59)
2 11 (11) 108 (9) 13 (13) 41 (11) 17 (12) 129 (9) 7 (11) 20 (15)
3 2 (2) 2 (<1) 2 (2) 9 (2) 2 (1) 9 (1) 2 (3) 2 (1)
4 0 0 0 1 (<1) 0 1 (0) 0 0
Metastatic site, n (%)a
Liver 69 (66) 849 (73) 73 (70) 253 (69) 98 (67) 1014 (73) 44 (70) 88 (64)
Lung 29 (28) 323 (28) 31 (30) 100 (27) 42 (29) 385 (28) 18 (29) 38 (28)
Bone 1 (1) 45 (4) 2 (2) 8 (2) 2 (1) 50 (4) 1 (2) 3 (2)
Other 32 (30) 311 (27) 22 (21) 82 (22) 41 (28) 361 (25) 14 (22) 32 (23)
No. of metastatic sites,
n (%)
(n = 100) (n = 1105) (n = 102) (n = 335) (n = 140) (n = 1317) (n = 62) (n = 123)
1 73 (73) 732 (66) 78 (76) 238 (71) 104 (74) 883 (67) 47 (76) 87 (71)
>1 27 (27) 373 (34) 24 (24) 97 (29) 36 (26) 434 (33) 15 (24) 36 (29)
Local recurrence, % 44 (45) 526 (51) 40 (42) 176 (53) 58 (42) 638 (51) 26 (46) 64 (51)
Median CEA, ng/mL
(range)











(n = 53) (n = 670) (n = 47) (n = 190) (n = 73) (n = 786) (n = 27) (n = 74)
Adjuvant 35 (66) 453 (68) 33 (70) 127 (67) 47 (64) 534 (68) 21 (78) 46 (62)
Neoadjuvant 9 (17) 67 (10) 2 (4) 24 (13) 10 (14) 79 (10) 1 (4) 12 (16)
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatients could have >1 metastatic site.
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similar PFS observed with oxaliplatin/irinotecan regimens in
the older age groups (≥70 and ≥75 years) compared with the
younger age groups is likely to be the result of the selection
of fewer but healthier patients better able to tolerate these
regimens (for example, 66.0% of patients ≥75 years of ageTable 3 Overall investigator-assessed response rate to bevaci
Response, n (%) Age <70 years (n = 1297) Age ≥70 years (n
Complete response 104 (8) 34 (7)
Partial response 645 (50) 209 (44)
Stable disease 348 (27) 139 (29)
Progressive disease 96 (7) 45 (9)
Not evaluable 41 (3) 12 (3)received oxaliplatin/irinotecan regimens versus 76.5% of
patients ≥70 years of age).
Similarly, evaluation of OS by chemotherapy regimen and
age found OS to be higher in patients <70 and <75 years of
age receiving oxaliplatin/irinotecan compared with those
receiving 5-FU/capecitabine (<70 vs. ≥70 years: 26.6 andzumab-based therapy according to patient age
= 480) Age <75 years (n = 1571) Age ≥75 years (n = 206)
139 (9) 17 (8)
734 (47) 77 (37)
461 (29) 72 (35)
115 (7) 17 (8)
122 (8) 23 (11)
Figure 2 Progression-free (PFS) and overall survival (OS) according to age. (A) PFS according to Age (<70 and ≥70 years); (B) PFS
according to Age (<75 and ≥75 years); (C) OS according to Age (<70 and ≥70 years); (D) OS according to Age (<75 and ≥75 years). OS: overall
survival, PFS: progression-free survival.
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http://www.biomedcentral.com/1471-2407/14/76122.9 months, log-rank test p = 0.37; <75 vs. ≥75 years: 26.2
and 22.4 months, log-rank test p = 0.13), whereas there was
no difference between oxaliplatin/irinotecan and 5-FU/cap-
ecitabine regimens was observed in patients ≥70 years ofage (23.0 and 21.1 months, respectively; log-rank test p =
0.46; Figure 3C) and the outcome appeared to be reversed
in patients ≥75 years of age (18.5 and 24.0 months, respect-
ively; log-rank test p = 0.34; Figure 3D).
Figure 3 Progression-free (PFS) and overall survival (OS) according to age and chemotherapy regimen. (A) PFS according to age and
chemotherapy regimen (<70 and ≥70 years); (B) PFS according to age and chemotherapy regimen (<75 and ≥75 years); (C) OS according
to age and chemotherapy regimen (<70 and ≥70 years); (D) OS according to age and chemotherapy regimen (<75 and ≥75 years).
FU/CAP: 5-fluorouracil-/capecitabine-based chemotherapy; OS: overall survival, OX/IRI: oxaliplatin-/irinotecan-based chemotherapy, PFS:
progression-free survival.
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In total, 270 potentially treatment-related adverse reac-
tions were reported; of these 72 (27%) were considered
to be serious (21% patients aged <70 years and 45% in
those aged ≥70 years; 26% patients aged <75 years and
30% in those aged ≥75 years). The incidence of
treatment-related adverse events was similar in patients
aged <70, ≥70, <75 years and ≥75 years (Table 4).The rate of premature withdrawal from the study was
similar in both age group comparisons (<70 years 52%
vs. ≥70 years 50%; <75 years 48% vs. ≥75 years 52%).
More patients ≥75 years of age withdrew from the study
because of a serious adverse event (10% vs. 6% of
patients aged <75 years) but no difference was observed
in those aged <70 vs. ≥70 years (6% vs. 7%). More
patients ≥70 or ≥75 years of age withdrew because of
Table 4 Treatment-related adverse events (≥0.4%) according to patient age
Adverse event, n (%) Age <70 years (n = 1297) ge ≥70 years (n = 480) Age <75 years (n = 1571) Age ≥75 years (n = 206)
Diarrhoea 36 (2.8) 13 (2.7) 45 (2.9) 4 (1.9)
Nausea 29 (2.2) 4 (0.8) 30 (1.9) 3 (1.5)
Hypertension 15 (1.2) 8 (1.7) 23 (1.5) 0
Bleeding 17 (1.3) 4 (0.8) 18 (1.1) 3 (1.5)
Leucopenia 7 (0.5) 1 (0.2) 8 (0.5) 0
Infection 6 (0.5) 2 (0.4) 8 (0.5) 0
Proteinuria 5 (0.4) 2 (0.4) 5 (0.3) 2 (1.0)
Phlebitis/thrombosis/embolism 11 (0.8) 6 (1.3) 15 (1.0) 2 (1.0)
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ively), while more patients aged <70 and <75 years with-
drew from the study because of planned surgery (7% vs.
4%, and 7% vs. 1%, respectively).Discussion
The ITT population in this observational study had a me-
dian PFS of 10.2 months, which is consistent with those
reported in the phase III trials by Hurwitz et al. [6] and
Saltz et al. [8] (10.6 and 9.4 months, respectively), and the
Bevacizumab Expanded Access Trial (BEAT) study [14],
the BRiTE study [12], the Avastin® Registry: Investigation
of Effectiveness and Safety (ARIES) study [15], the Panitu-
mumab Advanced Colorectal Cancer Evaluation (PACCE)
study [16], and the HORIZON III study [17] (10.8, 9.9,
10.3, 10.5 and 10.3 months, respectively). Other observa-
tional cohort studies have reported median PFS values in
the same range as our findings [18,19].
Evaluation of PFS and OS by patient age found both to
be significantly greater in patients aged <70 vs. ≥70 years
and <75 vs. ≥75 years, despite the fact that median age at
primary diagnosis of colorectal cancer in Germany is
69 years [20]. While the OS data are in agreement with
findings from the BRiTE study, in which median OS was
seen to decrease from 24.6 months in patients <65 years
of age to 16.8 months in those >80 years [12], the decrease
in PFS with increasing age was not observed in either the
BRiTE study [21] or the bevacizumab pooled analysis [11].
Interestingly, in ARIES, a US observational cohort study,
there were slight reductions in PFS (10.3 vs. 9.9 months)
and OS (25.1 vs. 19.6 months) in mCRC patients ≥70 years
compared with those <70 years of age receiving bevacizu-
mab and chemotherapy in the first-line setting, but neither
PFS (7.9 vs. 7.9 months) nor OS (18.7 vs. 17.2 months) dif-
fered in the second-line setting when comparing the two
age categories [22,23]. Furthermore, in the randomised
AGITG MAX study, the improvement in PFS observed
when bevacizumab was added to the existing chemother-
apy regimen was similar in those patients ≥75 years of age
compared with younger patients [24].Overall, this analysis of elderly patients who participated
in a large, community-based German observational cohort
study shows that the use of bevacizumab plus chemother-
apy is an effective first-line treatment option for patients
with mCRC, independent of age. Nevertheless, as would be
expected, median PFS and OS were significantly longer in
patients aged <70 and <75 years than in the respective older
patient groups, but there was no significant difference in
the duration of bevacizumab therapy between the two age
group comparisons. One possible explanation for this is
that, despite both age groups being well balanced regards
to most baseline characteristics, patients ≥70 or ≥75 years
of age had a poorer ECOG performance status compared
with the respective younger age group. This is likely to
result in a more conservative, less intensive, approach to
selecting the chemotherapy regimens for older patients (see
below), as well as – for interpretation of the OS – less
frequent use of all available drugs in subsequent treat-
ments. The elderly group might also have a poorer general
prognosis and certainly have a higher probability of non-
tumour-related death.
The possibility that patients in the older age groups re-
ceived less intensive therapy is supported when comparing
the first-line chemotherapy regimens used. Fewer patients
aged ≥75 years received bevacizumab plus doublet combi-
nations at the start of treatment (60% vs. 86% of patients
aged <75 years) while more patients aged ≥75 years
received bevacizumab plus 5-FU or capecitabine alone
(31% vs. 9% of patients aged <75 years). Evaluation of out-
come according to chemotherapy regimen and age found
that there were no differences in PFS and OS between age
groups when treated with bevacizumab plus fluoropyrimi-
dine monotherapy, but both PFS and OS were longer in
patients aged <70 vs. ≥70 years and <75 vs. ≥75 years
when treated with bevacizumab plus doublet combination
chemotherapy. While the comparative efficacy in terms of
PFS and OS of bevacizumab plus fluoropyrimidine mono-
therapy in younger and older patients appears to be in line
with that reported in the ARIES study [21], the reason for
the lack of increase in both PFS and OS with bevacizumab
plus doublet chemotherapy in patients ≥75 years of age
Hofheinz et al. BMC Cancer 2014, 14:761 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/761remains unclear. It is possible that these findings are the
result of the lower numbers of patients in each subgroup,
or that these particular patients had a worse prognosis.
Observational cohort studies allow the collection of data
on the ‘real-world’ incidence and time to onset of
treatment-related adverse events in general clinical practice,
together with monitoring for the occurrence of any new
safety signals. The incidence of treatment-related adverse
events was similar in patients aged <70 vs. ≥70 years and
those <75 vs. ≥75 years, as was the incidence of events con-
sidered to be serious. The rate of premature withdrawal
from the study was similar in both age groups, but more
patients the older age groups withdrew because of a serious
adverse event or treatment refusal while more patients in
the younger age groups withdrew because of planned sur-
gery. The rate of adverse events of interest for bevacizumab
was low in this study of German patients and was, overall,
less than those reported in the BEAT [14] and BRiTE stud-
ies [21]; indeed, no increase in the incidence of arterial
thromboembolosim in elderly patients was observed here
in contrast to the increases reported in the pooled analysis
of four randomised studies [11] and the BRiTE study [21].
It is possible that these differences could be the result of
the way in which adverse event data were retrieved. Overall,
no new safety signals were detected.
There are limitations that must be considered when
interpreting findings from observational studies, with their
inherent bias when selecting patients for specific treat-
ment and maintenance strategies and when assessing
progression and response. Nevertheless, minimal patient
selection criteria were used and all patients scheduled to
be treated with bevacizumab in the post-approval period
were included in the study. Consequently, the population
is more likely to be representative of the general oncology
population in Germany (as is shown by the age distribu-
tion), and the study provides valuable information on the
use of bevacizumab under the conditions and specifica-
tions of the German healthcare system.
This observational study only documented patients
treated with bevacizumab; it might have been of interest
to include a record of the reasons for which patients
were excluded from bevacizumab therapy, but this was
beyond the scope of the study.
Conclusion
First-line bevacizumab-based treatment combinations were
used successfully in German patients with mCRC, and also
specifically in individuals ≥75 years of age. Findings from
the current analysis suggest that for medically fit elderly
patients chemotherapy doublets with bevacizumab may be
regarded as a reasonable treatment option, although this
should be interpreted with caution as the randomised,
open-label FOCUS2 trial reported that the addition of oxa-
liplatin to fluoropyrimidine therapy versus no addition didnot provide a significant improvement in PFS [10]. How-
ever, in line with findings from the AVEX trial [9], mono-
therapy using 5-FU or capecitabine in conjunction with
bevacizumab was shown to result in promising PFS and OS
data in elderly mCRC patients.
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